↓ Skip to main content

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Overview of attention for article published in Future Oncology, February 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
4 X users
patent
1 patent
video
1 YouTube creator
podcasts
1 podcast

Readers on

mendeley
164 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Published in
Future Oncology, February 2019
DOI 10.2217/fon-2018-0609
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 164 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 16 10%
Researcher 15 9%
Student > Bachelor 14 9%
Other 13 8%
Student > Ph. D. Student 13 8%
Other 29 18%
Unknown 64 39%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 54 33%
Biochemistry, Genetics and Molecular Biology 13 8%
Pharmacology, Toxicology and Pharmaceutical Science 9 5%
Nursing and Health Professions 5 3%
Agricultural and Biological Sciences 5 3%
Other 10 6%
Unknown 68 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2024.
All research outputs
#2,170,537
of 34,411,289 outputs
Outputs from Future Oncology
#131
of 2,762 outputs
Outputs of similar age
#39,751
of 488,793 outputs
Outputs of similar age from Future Oncology
#4
of 42 outputs
Altmetric has tracked 34,411,289 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,762 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 488,793 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.